# A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

> **NCT05592990** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- Achilles Tendinopathy

## Interventions

- **DRUG:** NGI226
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05592990
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-14
- **Primary completion:** 2026-02-03
- **Final completion:** 2026-02-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05592990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05592990, "A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05592990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*